Cervical Cancer Susceptible Population Classification
Conditions
Brief summary
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.
Interventions
GENETICPCR and sequence
sequence the mutatation SNPs
Sponsors
Anhui Provincial Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Subjects aged \>=18 years at time of consent 2. Intended to undergo screening colposcopy 3. Considered by a physician or healthcare provider as being of average risk for cervical cancer 4. Willing to consent to blood draw cervical disease treatments 5. Willing to sonsent to follow-up for five years as per protocol
Exclusion criteria
1. History of cervical cancer 2. History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study) 3. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs. 4. Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent 5. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evalutaiton of the SNPs test in an average cervical cancer patients screening episode | two years |
Secondary
| Measure | Time frame |
|---|---|
| Classified susceptied person into different ladders | two years |
Countries
China
Contacts
Primary ContactYingying Wang, Doctor
Backup ContactTingting Zhao, Master
Outcome results
None listed